Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling

Neomal S Sandanayake; Stephane Camuzeaux; John Sinclair; Oleg Blyuss; Fausto Andreola; Michael H Chapman; George J Webster; Ross C Smith; John F Timms; Stephen P Pereira

doi:10.1186/1472-6890-14-7

Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling

Neomal S Sandanayake, Stephane Camuzeaux, John Sinclair, Oleg Blyuss, Fausto Andreola, Michael H Chapman, George J Webster, Ross C Smith, John F Timms, Stephen P Pereira

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

BACKGROUND: The aim of this discovery study was the identification of peptide serum biomarkers for detecting biliary tract cancer (BTC) using samples from healthy volunteers and benign cases of biliary disease as control groups. This work was based on the hypothesis that cancer-specific exopeptidases exist and that their activities in serum can generate cancer-predictive peptide fragments from circulating proteins during coagulation.

METHODS: This case control study used a semi-automated platform incorporating polypeptide extraction linked to matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) to profile 92 patient serum samples. Predictive models were generated to test a validation serum set from BTC cases and healthy volunteers.

RESULTS: Several peptide peaks were found that could significantly differentiate BTC patients from healthy controls and benign biliary disease. A predictive model resulted in a sensitivity of 100% and a specificity of 93.8% in detecting BTC in the validation set, whilst another model gave a sensitivity of 79.5% and a specificity of 83.9% in discriminating BTC from benign biliary disease samples in the training set. Discriminatory peaks were identified by tandem MS as fragments of abundant clotting proteins.

CONCLUSIONS: Serum MALDI MS peptide signatures can accurately discriminate patients with BTC from healthy volunteers.

Original language	English
Pages (from-to)	7
Journal	Journal of Clinical Pathology
Volume	14
Issue number	1
DOIs	https://doi.org/10.1186/1472-6890-14-7
Publication status	Published - 4 Feb 2014

Access to Document

10.1186/1472-6890-14-7

https://discovery.ucl.ac.uk/id/eprint/1422245/Licence: CC BY

Cite this

@article{51d4c83765d442499fe1600d7a85a576,

title = "Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling",

abstract = "BACKGROUND: The aim of this discovery study was the identification of peptide serum biomarkers for detecting biliary tract cancer (BTC) using samples from healthy volunteers and benign cases of biliary disease as control groups. This work was based on the hypothesis that cancer-specific exopeptidases exist and that their activities in serum can generate cancer-predictive peptide fragments from circulating proteins during coagulation.METHODS: This case control study used a semi-automated platform incorporating polypeptide extraction linked to matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) to profile 92 patient serum samples. Predictive models were generated to test a validation serum set from BTC cases and healthy volunteers.RESULTS: Several peptide peaks were found that could significantly differentiate BTC patients from healthy controls and benign biliary disease. A predictive model resulted in a sensitivity of 100% and a specificity of 93.8% in detecting BTC in the validation set, whilst another model gave a sensitivity of 79.5% and a specificity of 83.9% in discriminating BTC from benign biliary disease samples in the training set. Discriminatory peaks were identified by tandem MS as fragments of abundant clotting proteins.CONCLUSIONS: Serum MALDI MS peptide signatures can accurately discriminate patients with BTC from healthy volunteers.",

author = "Sandanayake, {Neomal S} and Stephane Camuzeaux and John Sinclair and Oleg Blyuss and Fausto Andreola and Chapman, {Michael H} and Webster, {George J} and Smith, {Ross C} and Timms, {John F} and Pereira, {Stephen P}",

year = "2014",

month = feb,

day = "4",

doi = "10.1186/1472-6890-14-7",

language = "English",

volume = "14",

pages = "7",

journal = "Journal of Clinical Pathology",

issn = "1472-6890",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling

AU - Sandanayake, Neomal S

AU - Camuzeaux, Stephane

AU - Sinclair, John

AU - Blyuss, Oleg

AU - Andreola, Fausto

AU - Chapman, Michael H

AU - Webster, George J

AU - Smith, Ross C

AU - Timms, John F

AU - Pereira, Stephen P

PY - 2014/2/4

Y1 - 2014/2/4

N2 - BACKGROUND: The aim of this discovery study was the identification of peptide serum biomarkers for detecting biliary tract cancer (BTC) using samples from healthy volunteers and benign cases of biliary disease as control groups. This work was based on the hypothesis that cancer-specific exopeptidases exist and that their activities in serum can generate cancer-predictive peptide fragments from circulating proteins during coagulation.METHODS: This case control study used a semi-automated platform incorporating polypeptide extraction linked to matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) to profile 92 patient serum samples. Predictive models were generated to test a validation serum set from BTC cases and healthy volunteers.RESULTS: Several peptide peaks were found that could significantly differentiate BTC patients from healthy controls and benign biliary disease. A predictive model resulted in a sensitivity of 100% and a specificity of 93.8% in detecting BTC in the validation set, whilst another model gave a sensitivity of 79.5% and a specificity of 83.9% in discriminating BTC from benign biliary disease samples in the training set. Discriminatory peaks were identified by tandem MS as fragments of abundant clotting proteins.CONCLUSIONS: Serum MALDI MS peptide signatures can accurately discriminate patients with BTC from healthy volunteers.

AB - BACKGROUND: The aim of this discovery study was the identification of peptide serum biomarkers for detecting biliary tract cancer (BTC) using samples from healthy volunteers and benign cases of biliary disease as control groups. This work was based on the hypothesis that cancer-specific exopeptidases exist and that their activities in serum can generate cancer-predictive peptide fragments from circulating proteins during coagulation.METHODS: This case control study used a semi-automated platform incorporating polypeptide extraction linked to matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) to profile 92 patient serum samples. Predictive models were generated to test a validation serum set from BTC cases and healthy volunteers.RESULTS: Several peptide peaks were found that could significantly differentiate BTC patients from healthy controls and benign biliary disease. A predictive model resulted in a sensitivity of 100% and a specificity of 93.8% in detecting BTC in the validation set, whilst another model gave a sensitivity of 79.5% and a specificity of 83.9% in discriminating BTC from benign biliary disease samples in the training set. Discriminatory peaks were identified by tandem MS as fragments of abundant clotting proteins.CONCLUSIONS: Serum MALDI MS peptide signatures can accurately discriminate patients with BTC from healthy volunteers.

U2 - 10.1186/1472-6890-14-7

DO - 10.1186/1472-6890-14-7

M3 - Article

C2 - 24495412

SN - 1472-6890

VL - 14

SP - 7

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

IS - 1

ER -

Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling

Abstract

Access to Document

Fingerprint

Cite this